UCB's Bimzelx Close To Challenging Major Psoriasis Players

With the drug demonstrating superiority over approved psoriasis therapies such as Cosentyx, Stelara and Humira in clinical trials, UCB's bimekizumab will shortly compete against these well-entrenched rivals on the European market, following a thumbs-up from the CHMP.